Table 1.

Effects of extended-release niacin and a combination of extended-release niacin and lovastatin, relative to placebo, on fasting and non-fasting plasma lipid levels.

	Placebo	Niacin	Niacin+ Lovastatin	Change (1)	Change (2)	Change (3)
Fasting	mg/dL	mg/dL	mg/dL
TC	243±35	209±28	163±22	−34±22 (0.01)	−80±30 (0.0001)	−46±13 (0.003)
TG *	343 (221–582)	174 (90–310)	164 (111–242)	−176±202 (0.005)	−194±182 (0.006)	−18±88 (0.56)
LDL-C	126±31	124±21	87±18	−3±12 (0.44)	−40±17 (0.0001)	−37±11 (0.0001)
HDL-C	34±5	46±9	46±6	+12±8 (0.01)	+11±5 (0.01)	0±5 (0.67)
Nonfasting
TC	224±39	199±29	157±25	−25±25 (0.14)	−67±31 (0.01)	−43±22 (0.03)
TG *	382 (260–518)	259 (127–449)	243 (209–285)	−115±195 (0.04)	−151±123 (0.05)	−35±128 (0.85)
LDL-C	117±38	115±16	78±20	−2±24 (0.59)	−39±22 (0.01)	−37±14 (0.01)
HDL-C	30±6	43±9	41±6	+13±7 (0.001)	+11±4 (0.001)	−2±5 (0.11)

^*variable was log transformed before analysis and is shown as geometric mean (min-max); all other variables shown as mean±SD;

1: mean±SD of the difference between Niacin and Placebo (P value)

2: mean±SD of the difference between Niacin+Lovastatin and Placebo (P value)

3: mean±SD of the difference between Niacin+Lovastatin and Niacin (P value)